NC-LENOVO/FORMULA-1
10.3.2022 14:32:13 CET | Business Wire | Press release
Formula 1 and Lenovo announced today that Lenovo is an Official Partner ahead of the upcoming 2022 season. The multi-year deal will see Lenovo’s cutting-edge technology used across Formula 1’s operations as it continues to bring the highest-level of racing and entertainment to its worldwide fanbase. As global leaders in their respective fields, Formula 1 and Lenovo want to push the boundaries of what’s possible when combining sports with advanced technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220310005287/en/
Over the next few years, the partnership will involve Lenovo’s technology being used across the Formula 1 organization, both back at its base and at races. Lenovo’s hardware devices, as well as High Performance Computing and server solutions will be increasingly integrated throughout the organisation’s operations. From running powerful on-premises data collection solutions to producing higher quality content and supporting broadcast applications, the Formula 1 and Lenovo collaboration will result in a better experience for fans.
The partnership will drive global visibility of Lenovo, showcasing Lenovo’s capabilities on a global scale and integrating industry-leading hardware technology at the heart of Formula 1. It plans to leverage Lenovo’s extensive selection of premium hardware as well as innovative next-generation technology such as augmented and virtual reality, as F1 continues to connect fans with the sport in new and more engaging ways.
Earlier this year, F1 announced that it has extended its commitment to create employment and education opportunities for underrepresented groups, in the form of ten engineering scholarships each year through to 2025. Lenovo is also focused on diversity and inclusion and removing barriers, and through the partnership will work with F1 on projects related to this important area.
Stefano Domenicali, President & CEO of Formula 1, said:
“As we prepare for our record-breaking season, it is exciting to welcome Lenovo to the team and for us to join forces with a global leader in technology. Like everything in Formula 1, precision and detail are everything, and Lenovo will be at the forefront of providing their experience and innovative technologies to our operations throughout the season. Our fans expect the best from everything we do, and Lenovo is the perfect partner in terms of its premium hardware offerings. We are entering a new era of our sport and we’re committed to delivering a high-quality experience for our dedicated followers around the world.”
Yang Yuanqing, Chairman & CEO of Lenovo, said:
“We are proud to announce our new global partnership with Formula 1, the world’s most prestigious motor racing competition, to engage half a billion fans all over the world with exciting, innovative experiences. This partnership is based on our shared passion for innovation, performance, and the winning spirit. Together Lenovo and Formula 1 will push the limits of technology to help shape a faster, smarter, and more sustainable future.”
Luca Rossi, President of Intelligent Devices Group, Lenovo, said:
“Partnering with Formula 1 to deploy Lenovo’s smarter solutions across the organization, from base operations to the stunning excitement of the Grands Prix, will help push the boundaries of what is possible and transform the racing experience. Formula 1 is focused on its digital transformation and continuing to surprise and delight its fans. Lenovo’s portfolio of hardware, services and solutions will be key to helping Formula 1 create new ways for fans around the world to experience the same thrills you’d experience track side.”
About Formula 1®
Formula 1® racing began in 1950 and is the world’s most prestigious motor racing competition, as well as the world’s most popular annual sporting series. Formula One World Championship Limited is part of Formula 1® and holds the exclusive commercial rights to the FIA Formula One World Championship™. Formula 1® is a subsidiary of Liberty Media Corporation (NASDAQ: LSXMA, LSXMB, LSXMK, BATRA, BATRK, FWONA, FWONK) attributed to the Formula One Group tracking stock. The F1 logo, F1 FORMULA 1 logo, FORMULA 1, F1, FIA FORMULA ONE WORLD CHAMPIONSHIP, GRAND PRIX, PADDOCK CLUB and related marks are trademarks of Formula One Licensing BV, a Formula 1 company. All rights reserved.
About Lenovo
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$60 billion revenue Fortune Global 500 company serving customers in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that power (through devices and infrastructure) and empower (through solutions, services and software) millions of customers every day and together create a more inclusive, trustworthy and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com , and read about the latest news via our StoryHub .
LENOVO is a trademark of Lenovo.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005287/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom